The potential of mesenchymal stem cell therapy for chronic lung disease
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Introduction: Mesenchymal stem/stromal cells (MSCs) have been shown to improve lung function and survival in chronic inflammatory lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), pulmonary arterial hypertension (PAH), and silicosis.Areas covered: This review covers rationale for the use of MSC therapy, along with preclinical studies and clinical trials with MSC therapy in chronic lung diseases.Expert opinion: MSC therapy holds promise for the treatment of chronic lung diseases, mainly when administered at early stages. In clinical trials, MSC administration was safe, but associated with limited effects on clinical outcomes. Further studies are required to elucidate unresolved issues, including optimal MSC source and dose, route of administration, and frequency (single vs. multiple-dose regimens). A better understanding of the mechanisms of MSC action, local microenvironment of each disease, and development of strategies to potentiate the beneficial effects of MSCs may improve outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Islam, M. N., Das, S. R., Emin, M. T., Wei, M., Sun, L., Westphalen, K., Rowlands, D. J., Quadri, S. K., Bhattacharya, S., & Bhattacharya, J. (2012) · Nature Medicine · doi:10.1038/nm.2736 · Cited by 1,585 · cited 1×
“bridges or through extracellular vesicles [16,17]; protection against microorganisms by secreting antibacterial peptides, and by increasingmonocyte phagocytic activity [18]; modulation of inflammation by promoting an anti-inflammatory phenotype in alveolar macrophages (M2 cells) and T regulatory cells, by reducing act…”
BackgroundMesenchymal stem cells use extracellular vesicles to outsource mitophagy and shuttle microRNAs
Phinney, D. G., Di Giuseppe, M., Njah, J., Sala, E., Shiva, S., St Croix, C. M., Stolz, D. B., Watkins, S. C., Di, Y. P., Leikauf, G. D., et al. (2015) · Nature Communications · doi:10.1038/ncomms9472 · Cited by 1,007 · cited 3×
“domain-containing protein 1-mediated microvesicles [98].”
BackgroundMesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816 · cited 2×
“bridges or through extracellular vesicles [16,17]; protection against microorganisms by secreting antibacterial peptides, and by increasingmonocyte phagocytic activity [18]; modulation of inflammation by promoting an anti-inflammatory phenotype in alveolar macrophages (M2 cells) and T regulatory cells, by reducing act…”
BackgroundFrançois, M., Copland, I. B., Yuan, S., Romieu-Mourez, R., Waller, E. K., & Galipeau, J. (2012) · Cytotherapy · doi:10.3109/14653249.2011.623691 · Cited by 375 · cited 1×
“hMSCs (fresh or freezing [62], and their provenance (from younger or aging donors [63,64], from healthy or emphysematous donors [65]), other important parameters include cell 34 F.”
BackgroundFang, X., Neyrinck, A. P., Matthay, M. A., & Lee, J. W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.119917 · Cited by 258 · cited 1×
“increasing epithelial cell reabsorption of fluid through induction of luminal ion channels and basolateral aquaporins [15]; restoration of disease-depleted ATP stores, metabolic capacity, and”
BackgroundGlassberg, M. K., Minkiewicz, J., Toonkel, R. L., Simonet, E. S., Rubio, G. A., DiFede, D., Shafazand, S., Khan, A., Pujol, M. V., LaRussa, V. F., et al. (2017) · Chest · doi:10.1016/j.chest.2016.10.061 · Cited by 249
Cruz, F. F., Borg, Z. D., Goodwin, M., Sokocevic, D., Wagner, D., McKenna, D. H., Rocco, P. R. M., & Weiss, D. J. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0268 · Cited by 84
Self-citation
Cited by
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, M. I. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165878 · Cited by 1,114
The Role of MSC in Wound Healing, Scarring and Regeneration
Guillamat-Prats, R. (2021) · Cells · doi:10.3390/cells10071729 · Cited by 393
Inhalable dry powder mRNA vaccines based on extracellular vesicles
Popowski, K. D., Moatti, A., Scull, G., Silkstone, D., Lutz, H., López de Juan Abad, B., George, A., Belcher, E., Zhu, D., Mei, X., et al. (2022) · Matter · doi:10.1016/j.matt.2022.06.012 · Cited by 218
Controversies regarding transplantation of mesenchymal stem cells
Velikova, T., Dekova, T., & Miteva, D. G. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v14.i2.90554 · Cited by 12
Metadata
- Authors
- Cruz, F. F., & Rocco, P. R. M.
- Venue
- Expert Review of Respiratory Medicine
- Publisher
- Informa UK Limited
- Published
- 2019-10-15
- Volume
- 14
- Issue
- 1
- Pages
- 31-39
- ISSN
- 1747-6348 (ISSN-L)
- 1747-6356
- OpenAlex
- W2981000288
- Cited by
- 154
- References
- 9
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The potential of mesenchymal stem cell therapy for chronic lung disease. https://app.cochat.ai/papers/10.1080/17476348.2020.1679628
- The paper
- Cruz, F. F., & Rocco, P. R. M. (2020). The potential of mesenchymal stem cell therapy for chronic lung disease. Expert Review of Respiratory Medicine. https://doi.org/10.1080/17476348.2020.1679628
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.